ArticleBMC cancer2026
Establishment and characterization of a novel human ampullary carcinoma cell line derived from a Chinese patient.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
Ampullary carcinoma is an uncommon malignant neoplasm located in Vater's ampulla, necessitating comprehensive exploration of its pathogenesis and therapeutic alternatives. Currently, the available models of ampullary carcinoma are severely restricted, impeding the advancement of fundamental research. Consequently, further models of ampullary carcinoma are required to enhance pertinent fundamental research. This study reports the development of a novel Chinese-origin human ampullary carcinoma cell line, named DPC-X2, utilizing fresh primary tumor tissue from ampullary carcinoma. DPC-X2 has been consistently passaged for more than 60 generations, exhibiting a population doubling time of around 95 h. The cells display atypical shape and distinct heterogeneity. STR profiling verifies that DPC-X2 is a unique human ampullary carcinoma cell line. Karyotype analysis indicates that all DPC-X2 cells have hyper-triploid karyotypes, characterized by a typical karyotype of 100, XXXX der(4), der(6), der(7), inv(9), der(12), der(13), der(19). The xenograft tumor development rate in NXG mice was 66.67%. This cell line exhibits sensitive to gemcitabine while demonstrating resistance to oxaliplatin, fluorouracil, and albumin-bound paclitaxel. DPC-X2 may be an important model for investigating the pathogenesis of ampullary carcinoma and for pharmaceutical development research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.